Vident Advisory
BEAM icon

Vident Advisory’s Beam Therapeutics BEAM Stock Holding History

Vident Advisory’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,190
Closed -$225K – 1458
2024
Q3 		$225K Sell
9,190
-9,263
-50% -$239K 0.01% 1261
2024
Q2 		$432K Sell
18,453
-947
-5% -$23.3K 0.01% 969
2024
Q1 		$641K Buy
19,400
+3,408
+21% +$106K 0.01% 722
2023
Q4 		$435K Buy
15,992
+1,546
+11% +$38.4K 0.01% 838
2023
Q3 		$347K Buy
+14,446
New +$387K 0.01% 835

Other funds holding BEAM

Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Vident Advisory's BEAM Position: Q4 2024 in Review

Vident Advisory sold out of Beam Therapeutics (BEAM) in Q4 2024, closing a stake of 9,190 shares — an estimated $225K sold.

Vident Advisory first reported a position in BEAM in Q3 2023 and held it in 5 quarters. The position peaked at $641K in Q1 2024. 231 funds tracked by Wall St. Rank hold BEAM as of Q4 2024.

  • Vident Advisory reported no remaining Beam Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Vident Advisory sold 9,190 Beam Therapeutics shares in Q4 2024, an estimated $225K.
  • Vident Advisory first reported a position in Beam Therapeutics in Q3 2023 and held it in 5 quarters.
  • Vident Advisory's Beam Therapeutics position peaked at $641K in Q1 2024.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2024.

Based on Vident Advisory's 13F filing for Q4 2024, filed 14 Feb 2025.